<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diabetic retinopathy: Screening</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diabetic retinopathy: Screening</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diabetic retinopathy: Screening</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paolo S Silva, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Trobe, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 04, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The development of diabetic retinopathy (DR) occurs in nearly all persons with diabetes and remains a leading cause of blindness worldwide [<a href="#rid1">1</a>]. Despite the availability of highly effective treatment for the sight-threatening complications of diabetes, many persons with diabetes do not receive regular eye care examinations and sight-preserving treatments [<a href="#rid2">2</a>]. Moreover, not all patients achieve the levels of glycemic control demonstrated to reduce the risk of retinopathy in both type 1 and type 2 diabetes [<a href="#rid3">3,4</a>].</p><p>Early detection through screening programs and appropriate referral for therapy are important to preserve vision in individuals with diabetes. Issues related to screening for DR will be reviewed here. The pathogenesis, clinical findings, natural history, and treatment of this disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/1756.html" rel="external">"Diabetic retinopathy: Pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/1783.html" rel="external">"Diabetic retinopathy: Classification and clinical features"</a> and  <a class="medical medical_review" href="/d/html/1773.html" rel="external">"Diabetic retinopathy: Prevention and treatment"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">RATIONALE FOR SCREENING</span><span class="headingEndMark"> — </span>The onset of diabetic retinal complications is typically insidious, and patients remain generally asymptomatic and unaware of the disease during the early stages when treatment and medical management are most effective. The asymptomatic presentation of DR emphasizes the importance of retinal examinations to detect and evaluate disease severity and identify patients at risk for vision loss. The rate of DR progression may be rapid, and therapy can be beneficial for both symptom amelioration and reduction in the rate of disease progression.</p><p>The efficacy of laser photocoagulation and/or vascular endothelial growth factor (VEGF) inhibitors in preventing visual loss from proliferative diabetic retinopathy (PDR) and macular edema (ME) is well established in randomized trials. However, these therapies are more beneficial in preventing visual loss than reversing diminished visual acuity. Therefore, it is important to screen patients with diabetes regularly for the development of retinal disease and, when detected, to refer for sight-preserving therapy. (See  <a class="medical medical_review" href="/d/html/1773.html" rel="external">"Diabetic retinopathy: Prevention and treatment"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">METHOD OF SCREENING</span><span class="headingEndMark"> — </span>Initial screening can be accomplished with dilated fundus examination or retinal photography. Screening must be performed by those with expertise in the chosen modality (eg, ophthalmologist/optometrist experienced with diagnosing diabetic retinopathy [DR] or trained photographer and reader for retinal photography).</p><p>When previous examinations have been normal, subsequent examinations can be done with retinal photographs. A comprehensive examination is required for follow-up of abnormalities detected on retinal photographs. These recommendations are largely consistent with American Diabetes Association (ADA) guidelines [<a href="#rid5">5</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dilated fundus examination</strong> – Ophthalmoscopy by well-trained personnel on dilated fundi has been the standard screening method for DR. (The accuracy of ophthalmoscopy is substantially lower when performed by primary care physicians [<a href="#rid6">6</a>].) The availability of digital stereoscopic retinal imaging read by experts via telemedicine may improve retinopathy screening in areas with a shortage of eye care specialists [<a href="#rid7">7-9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Retinal photography</strong> – Digital stereoscopic retinal imaging takes 15 to 20 minutes, and some devices (nonmydriatic) may not require dilation of the pupil. The images can be interpreted remotely by an ophthalmologist or onsite using a validated automated computer algorithm to identify the presence of referable or vision-threatening disease. When compared with dilated ophthalmoscopic examination or the gold standard seven-field stereoscopic fundus photography for retinopathy screening, digital imaging (three fields) has good sensitivity and specificity for detecting DR [<a href="#rid10">10-13</a>]. As an example, in one study comparing digital imaging with dilated ophthalmoscopic examination, there was agreement in 86 percent of cases [<a href="#rid10">10</a>]. The majority of discordant diagnoses (35 of 46 eyes) were related to a greater frequency of finding mild to moderate nonproliferative diabetic retinopathy (NPDR) with digital images compared with ophthalmoscopic examination. Although there were few cases of macular edema (ME; six eyes), there was 100 percent concordance between the two modalities.</p><p></p><p class="bulletIndent1">There has been broader adoption of telemedicine programs for DR screening, which range from integration in primary care settings, prison or penal populations, remote areas with limited health care facilities, underserved populations, as well as in hospital-based or tertiary care facilities  (<a class="graphic graphic_picture graphicRef134139" href="/d/graphic/134139.html" rel="external">picture 1</a>). The use of telemedicine has been shown to overcome patient resistance to eye examinations through the use of nonmydriatic imaging and by locating imaging services at the point of diabetes care [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Automated evaluation of retinal photographs</strong> – Automated evaluation of digital retinal images uses a computer algorithm with the ability to continually learn and update parameters for detecting referable DR [<a href="#rid15">15-17</a>]. The use of artificial intelligence algorithms in evaluation of retinal images is not applicable to all clinical settings. In the United States, regulatory approval for retinal diagnostic software devices is limited to specific retinal cameras and target populations. All current devices require a retinal photographer to acquire images, and artificial intelligence algorithms are limited to use in eyes that have <strong>not</strong> been diagnosed previously with DR. Further, current artificial intelligence-enabled retinal diagnostic devices do not identify nondiabetic retinal diseases that may be present in patients with diabetes. The automated evaluation should not be used in pregnant women, in whom retinopathy can progress rapidly, as available devices are not intended for evaluation of rapidly changing retinopathy [<a href="#rid17">17</a>]. They also should not be used in patients with previously diagnosed severe NPDR, proliferative diabetic retinopathy (PDR), ME, radiation retinopathy, or retinal vein occlusion; those with a history of laser treatment, surgery, or injections in the eye; or those with any vision symptoms (eg, persistent vision loss, blurred vision, or floaters) [<a href="#rid17">17</a>]. In the United States, three retinal diagnostic devices have regulatory approval for DR screening [<a href="#rid18">18</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h1">SCREENING INITIATION AND FREQUENCY</span></p><p class="headingAnchor" id="H5"><span class="h2">When should screening begin?</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adults</strong> – In patients with type 2 diabetes, we suggest an initial comprehensive examination by an ophthalmologist or optometrist shortly after the diagnosis of diabetes is made  (<a class="graphic graphic_table graphicRef61833" href="/d/graphic/61833.html" rel="external">table 1</a>) [<a href="#rid5">5</a>]. In patients with type 1 diabetes, we suggest an initial comprehensive examination by an ophthalmologist or optometrist within five years after diagnosis.</p><p></p><p class="bulletIndent1">Type 2 diabetes is typically a disease with insidious onset, and some patients already have retinopathy at the time of diagnosis of hyperglycemia  (<a class="graphic graphic_figure graphicRef58736" href="/d/graphic/58736.html" rel="external">figure 1</a>). In contrast, it is unusual for patients with type 1 diabetes (under age 30 years) to develop retinopathy that requires specific ophthalmologic therapy earlier than five years after the onset of diabetes  (<a class="graphic graphic_figure graphicRef70042" href="/d/graphic/70042.html" rel="external">figure 2</a>). As an example, in 1613 patients with type 1 diabetes of less than five years' duration who were screened for enrollment in the Diabetes Control and Complications Trial (DCCT), 874 had evidence of DR either by fundus photography or <a class="drug drug_general" data-topicid="8461" href="/d/drug information/8461.html" rel="external">fluorescein</a> angiography [<a href="#rid19">19</a>]. However, none had proliferative diabetic retinopathy (PDR) requiring laser treatment, and only six (0.4 percent) had preproliferative retinopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children and adolescents</strong> – In children with type 1 diabetes, it is unusual to develop retinopathy prior to age 10 years. Initial screening in children and adolescents is reviewed separately. (See  <a class="medical medical_review" href="/d/html/5818.html" rel="external">"Complications and screening in children and adolescents with type 1 diabetes mellitus", section on 'Retinopathy'</a> and  <a class="medical medical_review" href="/d/html/5826.html" rel="external">"Chronic complications and screening in children and adolescents with type 2 diabetes mellitus", section on 'Retinopathy'</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Frequency of examinations</span><span class="headingEndMark"> — </span>The frequency of follow-up examinations should be individualized, with more frequent follow-up in patients who have abnormal findings or if retinopathy is progressing  (<a class="graphic graphic_table graphicRef61833" href="/d/graphic/61833.html" rel="external">table 1</a>) [<a href="#rid5">5</a>]. Patients with any level of diabetic retinopathy (DR) should be evaluated annually, with more severe disease requiring more frequent evaluation. Less frequent examinations (every two years) may be considered with the advice of an eye care professional in the setting of a normal examination and the absence of risk factors for progression [<a href="#rid20">20</a>]. An individualized schedule for ophthalmologic evaluation as well as for glycemic and blood pressure management, rather than a uniformly annual or biannual screening intervals, may be preferable and more cost effective [<a href="#rid21">21,22</a>].</p><p>Patients with diabetes who do not have DR are still at increased risk for age-associated vision loss related to refractive errors (correctable visual impairment), cataracts, and glaucoma (the latter two are more prevalent in persons with diabetes). Therefore, findings other than DR may dictate frequency of follow-up eye examinations. (See  <a class="medical medical_review" href="/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Routine eye examination'</a>.)</p><p>Few data have evaluated the frequency of follow-up examinations after the initial DR screening examination [<a href="#rid23">23-25</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 2 diabetes</strong> – In the Wisconsin Epidemiology Study of Diabetic Retinopathy (WESDR), patients with type 2 diabetes and no retinopathy on baseline examination (standard stereoscopic color fundus photographs) did not progress to PDR over four years [<a href="#rid23">23</a>]. For patients with type 2 diabetes on insulin therapy and without DR at baseline, the incidence of any DR at four years was 47 percent. Among those on insulin therapy and without PDR at baseline, 7 percent developed PDR over four years. For those not on insulin therapy, the rates of DR and PDR at four years were 34 and 2 percent, respectively [<a href="#rid26">26</a>]. Longer duration of diabetes, retinopathy on baseline examination, gross proteinuria, and poor glycemic management predicted greater risk of developing PDR.</p><p></p><p class="bulletIndent1">Similarly, a cohort study from the United Kingdom found that the incidence of sight-threatening DR (moderate preproliferative retinopathy or worse, or clinically significant macular edema [ME]) in patients with type 2 diabetes with no retinopathy on initial screening was 0.3 percent (95% CI 0.1-0.5) in the first year and 1.8 percent (95% CI 1.2-2.5) in the fifth year, suggesting that screening every three or four years may be adequate in those with normal initial examinations [<a href="#rid24">24</a>]. Yearly or more frequent screening was required for those with background or preproliferative retinopathy on initial screening.</p><p></p><p class="bulletIndent1">Based upon these studies, some health care organizations and auditing groups (such as the National Committee on Quality Assurance) have suggested that those who have no DR may be screened every two years. However, it is not clear if the results of the above studies are applicable to all patients with type 2 diabetes. As an example, the WESDR study individuals were White Americans of northern European extraction, and some studies suggest racial and ethnic variation in DR (see  <a class="medical medical_review" href="/d/html/1756.html" rel="external">"Diabetic retinopathy: Pathogenesis"</a>). In the Veterans Affairs Diabetes Trial (VADT), the prevalence of moderate to severe DR was higher for Hispanic American (36 percent) and Black American persons (29 percent) than for non-Hispanic White American persons (22 percent) [<a href="#rid27">27</a>]. The greater risk was reportedly independent of any imbalance in risk factors. Furthermore, it is not clear that the standards used in the WESDR study for evaluation of the photographs can be adopted nationwide. Finally, there is greater potential to lose patients to follow-up with less frequent screening intervals and may give the impression to patients that vision loss is unlikely and not a concern. (See  <a class="medical medical_review" href="/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Routine eye examination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 1 diabetes</strong> – The appearance and progression of retinopathy has been assessed regularly with scheduled fundus photography in patients with type 1 diabetes participating in the DCCT and Epidemiology of Diabetes Interventions and Complications (EDIC) study, giving rise to a mean 23.5 years of follow-up data [<a href="#rid21">21</a>]. Among almost 24,000 retinopathy examinations, 14.5 percent showed worsening from the previous visit, 7.8 percent showed improvement, and 77.7 percent showed no change. Higher glycated hemoglobin (A1C) levels were associated with a significantly increased risk of worsening retinopathy.</p><p></p><p class="bulletIndent1">A Markov model was used to calculate the probabilities of transitioning from lower levels of retinopathy with varying screening intervals. The time interval during which patients progressed from lower to higher categories of retinopathy was dependent upon the previous retinal examination and A1C level, with optimal screening intervals ranging from every three months among patients with severe nonproliferative diabetic retinopathy (NPDR) to every four years among those who had no retinopathy. This individualized schedule for retinopathy screening resulted in an overall reduction in the frequency of eye examinations and a substantial reduction in cost. These data support an individualized approach based on DR severity and systemic risk factors to tailor the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fextapps.bsc.gwu.edu%2Fshinypub%2Fedic%2Fretinopathy%2F&amp;token=DMPsWHHEAgzgsZdy9yeRgwbaGENUMpFHKpi%2BHjuhmN%2FdOvlZqNugsb9T5QnXIqMhoNDGBy8zSteA7j%2FUfWEU%2Fw%3D%3D&amp;TOPIC_ID=1755" target="_blank">optimal examination interval</a> for each patient.</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>The effect of pregnancy on the natural history of DR has been addressed in several studies; progression has been observed in 16 to 85 percent of patients, and the rate of progression may be accelerated. This topic is reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1783.html" rel="external">"Diabetic retinopathy: Classification and clinical features", section on 'Worsening during pregnancy'</a>.)</p><p>Because pregnancy may exacerbate underlying DR, women with diabetes who are planning pregnancy should have a comprehensive eye examination and be counseled on the risk of development and/or progression of DR  (<a class="graphic graphic_table graphicRef61833" href="/d/graphic/61833.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/4802.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control"</a>.)</p><p>Women with diabetes who become pregnant should have a comprehensive eye examination in the first trimester and have close follow-up throughout pregnancy and for one year postpartum. This guideline does not apply to women who develop gestational diabetes, as these women are not at increased risk for DR.</p><p class="headingAnchor" id="H9"><span class="h1">SCREENING IMPACT</span><span class="headingEndMark"> — </span>Two studies have addressed the value of screening for DR in type 1 and type 2 diabetes [<a href="#rid28">28,29</a>]. They concluded that, in patients with type 1 diabetes, annual screening (ophthalmoscopy with dilated pupils) for those without retinopathy and follow-up every six months for those with retinopathy followed by appropriate treatment would result in a saving of 70,000 to 80,000 person-years of sight and 60 to 80 million US dollars annually in the United States [<a href="#rid28">28</a>]. Comparable numbers for type 2 diabetes were over 94,000 person-years of sight and over 250 million US dollars per year [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H2847743510"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104442.html" rel="external">"Society guideline links: Diabetes mellitus in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/111575.html" rel="external">"Society guideline links: Diabetes mellitus in children"</a>.)</p><p class="headingAnchor" id="H432512"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15847.html" rel="external">"Patient education: Diabetic retinopathy (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H10"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Method of screening</strong> – In patients with diabetes, we recommend screening for diabetic retinopathy (DR) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Screening must be performed by those with expertise and can be accomplished with dilated fundus examination or retinal photography. (See <a class="local">'Method of screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initiation of screening</strong> – In patients with type 1 diabetes, we suggest initiating screening three to five years after diagnosis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). In patients with type 2 diabetes, we suggest initiating screening soon after the time of diagnosis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Screening initiation and frequency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequency of examinations</strong> – The frequency of follow-up examinations should be individualized.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonpregnant</strong> – In patients who are found to have retinopathy on initial screening examination, we suggest annual follow-up examinations (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). More frequent follow-up is necessary if retinopathy is progressing. Patients with macular edema (ME), severe nonproliferative diabetic retinopathy (NPDR), or proliferative diabetic retinopathy (PDR) should be closely followed by an ophthalmologist experienced in the management of DR. If there is no evidence of retinopathy on initial examination, less frequent examinations (every two years) may be adequate. (See <a class="local">'Screening initiation and frequency'</a> above and  <a class="medical medical_review" href="/d/html/1773.html" rel="external">"Diabetic retinopathy: Prevention and treatment"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Planning a pregnancy</strong> – Women with diabetes who are planning pregnancy should have a comprehensive eye examination and be counseled on the risk of development and/or progression of DR during pregnancy. (See  <a class="medical medical_review" href="/d/html/1783.html" rel="external">"Diabetic retinopathy: Classification and clinical features", section on 'Worsening during pregnancy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>During pregnancy</strong> – In pregnant women with preexisting diabetes who would not otherwise be due for screening, we suggest that such screening be performed during the first trimester (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). More frequent retinal evaluations are required during pregnancy and for one year postpartum  (<a class="graphic graphic_table graphicRef61833" href="/d/graphic/61833.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2">This guideline does not apply to women who develop gestational diabetes, as these women are not at increased risk for DR. (See <a class="local">'Pregnancy'</a> above.)</p><p></p><p class="headingAnchor" id="H3263859168"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David McCulloch, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vujosevic S, Aldington SJ, Silva P, et al. Screening for diabetic retinopathy: new perspectives and challenges. Lancet Diabetes Endocrinol 2020; 8:337.</a></li><li><a class="nounderline abstract_t">Schoenfeld ER, Greene JM, Wu SY, Leske MC. Patterns of adherence to diabetes vision care guidelines: baseline findings from the Diabetic Retinopathy Awareness Program. Ophthalmology 2001; 108:563.</a></li><li><a class="nounderline abstract_t">Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995; 102:647.</a></li><li><a class="nounderline abstract_t">Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47:S231.</a></li><li><a class="nounderline abstract_t">O'Hare JP, Hopper A, Madhaven C, et al. Adding retinal photography to screening for diabetic retinopathy: a prospective study in primary care. BMJ 1996; 312:679.</a></li><li><a class="nounderline abstract_t">Shi L, Wu H, Dong J, et al. Telemedicine for detecting diabetic retinopathy: a systematic review and meta-analysis. Br J Ophthalmol 2015; 99:823.</a></li><li><a class="nounderline abstract_t">Taylor CR, Merin LM, Salunga AM, et al. Improving diabetic retinopathy screening ratios using telemedicine-based digital retinal imaging technology: the Vine Hill study. Diabetes Care 2007; 30:574.</a></li><li><a class="nounderline abstract_t">Kirkizlar E, Serban N, Sisson JA, et al. Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration. Ophthalmology 2013; 120:2604.</a></li><li><a class="nounderline abstract_t">Ahmed J, Ward TP, Bursell SE, et al. The sensitivity and specificity of nonmydriatic digital stereoscopic retinal imaging in detecting diabetic retinopathy. Diabetes Care 2006; 29:2205.</a></li><li><a class="nounderline abstract_t">Vujosevic S, Benetti E, Massignan F, et al. Screening for diabetic retinopathy: 1 and 3 nonmydriatic 45-degree digital fundus photographs vs 7 standard early treatment diabetic retinopathy study fields. Am J Ophthalmol 2009; 148:111.</a></li><li><a class="nounderline abstract_t">Bragge P, Gruen RL, Chau M, et al. Screening for presence or absence of diabetic retinopathy: a meta-analysis. Arch Ophthalmol 2011; 129:435.</a></li><li><a class="nounderline abstract_t">Chasan JE, Delaune B, Maa AY, Lynch MG. Effect of a teleretinal screening program on eye care use and resources. JAMA Ophthalmol 2014; 132:1045.</a></li><li><a class="nounderline abstract_t">Salongcay RP, Silva PS. The Role of Teleophthalmology in the Management of Diabetic Retinopathy. Asia Pac J Ophthalmol (Phila) 2018; 7:17.</a></li><li><a class="nounderline abstract_t">Gulshan V, Peng L, Coram M, et al. Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs. JAMA 2016; 316:2402.</a></li><li><a class="nounderline abstract_t">Walton OB 4th, Garoon RB, Weng CY, et al. Evaluation of Automated Teleretinal Screening Program for Diabetic Retinopathy. JAMA Ophthalmol 2016; 134:204.</a></li><li class="breakAll">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm604357.htm?utm_campaign=PR_FDA%20permits%20AI%20device%20for%20diabetes%20eye%20problems&amp;utm_medium=email&amp;utm_source=Eloqua (Accessed on September 18, 2018).</li><li class="breakAll">U.S. Food and Drug Administration-approved artificial intelligence and machine learning-enabled medical devices. Available at: https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices (Accessed on October 10, 2023).</li><li><a class="nounderline abstract_t">Malone JI, Morrison AD, Pavan PR, et al. Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years' duration screened for the diabetes control and complications trial. Diabetes Care 2001; 24:522.</a></li><li><a class="nounderline abstract_t">Scanlon PH. Screening Intervals for Diabetic Retinopathy and Implications for Care. Curr Diab Rep 2017; 17:96.</a></li><li><a class="nounderline abstract_t">DCCT/EDIC Research Group, Nathan DM, Bebu I, et al. Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. N Engl J Med 2017; 376:1507.</a></li><li><a class="nounderline abstract_t">van der Heijden AA, Walraven I, van 't Riet E, et al. Validation of a model to estimate personalised screening frequency to monitor diabetic retinopathy. Diabetologia 2014; 57:1332.</a></li><li><a class="nounderline abstract_t">Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994; 112:1217.</a></li><li><a class="nounderline abstract_t">Younis N, Broadbent DM, Vora JP, et al. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003; 361:195.</a></li><li><a class="nounderline abstract_t">Thomas RL, Dunstan F, Luzio SD, et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. BMJ 2012; 344:e874.</a></li><li><a class="nounderline abstract_t">Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989; 107:244.</a></li><li><a class="nounderline abstract_t">Emanuele N, Sacks J, Klein R, et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care 2005; 28:1954.</a></li><li><a class="nounderline abstract_t">Javitt JC, Canner JK, Frank RG, et al. Detecting and treating retinopathy in patients with type I diabetes mellitus. A health policy model. Ophthalmology 1990; 97:483.</a></li><li><a class="nounderline abstract_t">Javitt JC, Aiello LP, Chiang Y, et al. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care 1994; 17:909.</a></li></ol></div><div id="topicVersionRevision">Topic 1755 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32113513" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Screening for diabetic retinopathy: new perspectives and challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11237912" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Patterns of adherence to diabetes vision care guidelines: baseline findings from the Diabetic Retinopathy Awareness Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7724182" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9742976" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38078577" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8597737" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adding retinal photography to screening for diabetic retinopathy: a prospective study in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25563767" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Telemedicine for detecting diabetic retinopathy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17327323" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Improving diabetic retinopathy screening ratios using telemedicine-based digital retinal imaging technology: the Vine Hill study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084501" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17003294" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The sensitivity and specificity of nonmydriatic digital stereoscopic retinal imaging in detecting diabetic retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19406376" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Screening for diabetic retinopathy: 1 and 3 nonmydriatic 45-degree digital fundus photographs vs 7 standard early treatment diabetic retinopathy study fields.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21149748" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Screening for presence or absence of diabetic retinopathy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24875731" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of a teleretinal screening program on eye care use and resources.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29376232" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Role of Teleophthalmology in the Management of Diabetic Retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27898976" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26720694" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evaluation of Automated Teleretinal Screening Program for Diabetic Retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26720694" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Evaluation of Automated Teleretinal Screening Program for Diabetic Retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26720694" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Evaluation of Automated Teleretinal Screening Program for Diabetic Retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11289479" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years' duration screened for the diabetes control and complications trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28875458" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Screening Intervals for Diabetic Retinopathy and Implications for Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28423305" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24763851" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Validation of a model to estimate personalised screening frequency to monitor diabetic retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7619101" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12547541" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22362115" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2644929" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043738" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2109299" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Detecting and treating retinopathy in patients with type I diabetes mellitus. A health policy model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7956643" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
